Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
スポンサーリンク
概要
- 論文の詳細を見る
1a-N-Stearoyl mitomycin C (MMC) and six 1a-N-substituted derivatives of MMC possessing the cholesteryl moiety with different spacers were synthesized, and their biopharmaceutical properties were studied to assess the feasibility of such derivatives as prodrugs for intravenously injectable liposomal sustained-release carrier systems. All compounds showed increased lipophilic indices (logk'_0) in high performance liquid chromatography. It was found that all the derivatives could be almost completely entrapped in liposomes, although MMC itself was hardly encapsulated. The derivatives with the exception of cholesteryloxycarbonyl MMC (II) and N-(cholesteryloxy-carbonyl)-4-aminophenylacetyl MMC (VI) were converted to the parent drug in rat serum. The suceptibility of the compounds to hydrolysis was strongly affected by the spacer structure between MMC and the cholesteryl moiety. Cholesteryloxyacetyl MMC (IV) was converted to MMC mainly by chemical hydrolysis. N-(Cholesteryloxycarbonyl)glycyl MMC (III) was also hydrolyzed to MMC chemically but in this case hydrolysis was accelerated in the presence of mouse, rat and human serum. No species differences were observed in these bioactivation phenomena. Entrapment of derivatives III and IV in liposomes resulted in enhancement of the stability against both chemical and enzymatic hydrolysis. The derivatives possessing the cholesteryl moiety were firmly associated with liposomes in the circulation, while stearoyl MMC (VIII) was rapidly recoved. These results suggest that derivatives III and IV have the potential to be utilized as lipophilic prodrugs for liposomal sustained-release carrier systems to be delivered by intravenous injection.
- 社団法人日本薬学会の論文
- 1988-08-25
著者
-
藤崎 二朗
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
藤崎 二郎
藤沢薬品工業探索研究所
-
藤崎 二郎
藤沢薬品工業
-
徳永 雄二
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
岩佐 知明
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
沢居 清治
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
加賀山 彰
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
藤崎 二郎
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,
-
徳永 雄二
Pharmaceutical Institute, Tohoku University
-
徳永 雄二
藤沢薬品工業 開発第二研
-
沢居 清治
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
加賀山 彰
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
-
岩佐 知明
Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.
関連論文
- Regional Capacities of Gastrointestinal Absorption and Lymphatic Transport for Lipid-Soluble Dyes in Rats
- Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles
- キット製剤の将来展望(E・薬剤学, 製剤学, 病院薬学)
- Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
- Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
- INDIRECT ELECTROREDUCTIVE CYCLIZATION FOR SYNTHESES OF KEY INTERMEDIATES OF SEVERAL INDOLE AND IPECAC ALKALOIDS
- Effect of Some Ionic and Nonionic Surfactants on the Intramuscular Absorption of Isonicotinamide
- O-66 セファメジンαノンバイアルキットの製剤設計 (2) : 製剤特性と機能性評価
- O-65 セファメジンαノンバイアルキットの製剤設計 (1) : 設計コンセプトと有用性評価
- 放出開始時間制御型経口投与システム (TES) の設計
- Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
- セファメジンαノンバイアルキットの容器設計と品質保証
- Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
- Biopharmaceutical Study of the Hepato-biliary Transport of Drugs. IV. Development of the Method to Investigate the Process of the Active Secretion of Drugs from the Hepatocytes into the Bile Canaliculi and Its Application to the Biliary Excretion of Organ